246 related articles for article (PubMed ID: 15980949)
1. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
Oyama Y; Kazama JJ; Omori K; Higuchi N; Kameda S; Yamamoto S; Ito Y; Maruyama H; Narita I; Gejyo F
Clin Exp Nephrol; 2005 Jun; 9(2):142-7. PubMed ID: 15980949
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.
Kazama JJ; Sato F; Omori K; Hama H; Yamamoto S; Maruyama H; Narita I; Gejyo F; Yamashita T; Fukumoto S; Fukagawa M
Kidney Int; 2005 Mar; 67(3):1120-5. PubMed ID: 15698453
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
[TBL] [Abstract][Full Text] [Related]
6. Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
Kazama JJ; Omori K; Higuchi N; Takahashi N; Ito Y; Maruyama H; Narita I; Cantor TL; Gao P; Gejyo F
Nephrol Dial Transplant; 2004 Apr; 19(4):892-7. PubMed ID: 15031346
[TBL] [Abstract][Full Text] [Related]
7. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
[TBL] [Abstract][Full Text] [Related]
10. Suppression of parathyroid hormone secretion in CAPD patients by intraperitoneal administration of Maxacalcitol.
Murakami K; Miyachi H; Watanabe A; Kawamura N; Fujii M; Koide S; Murase M; Kushimoto H; Hasegawa M; Tomita M; Hiki Y; Sugiyama S
Clin Exp Nephrol; 2004 Jun; 8(2):134-8. PubMed ID: 15235930
[TBL] [Abstract][Full Text] [Related]
11. Maxacalcitol is a possible less phosphatemic vitamin D analog.
Kazama JJ; Maruyama H; Narita I; Gejyo F
Ther Apher Dial; 2005 Aug; 9(4):352-4. PubMed ID: 16076381
[TBL] [Abstract][Full Text] [Related]
12. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
Vlassopoulos D; Noussias C; Revenas K; Hadjilouka-Mantaka A; Arvanitis D; Tzortzis G; Hadjiconstantinou V
Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180
[TBL] [Abstract][Full Text] [Related]
15. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
16. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
[TBL] [Abstract][Full Text] [Related]
17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
18. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
Honda H; Koiwa F; Ogata H; Shishido K; Sekiguchi T; Michihata T; Ogawa H; Mukai M; Takahashi K; Suzuki R; Kino K; Kato K; Yamamoto K; Kinugasa E; Akizawa T
Int J Clin Pharmacol Ther; 2014 May; 52(5):360-8. PubMed ID: 24569127
[TBL] [Abstract][Full Text] [Related]
19. Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism.
Hosaka K; Kazama JJ; Yamamoto S; Ito Y; Iino N; Maruyama H; Saito A; Narita I; Gejyo F
J Bone Miner Metab; 2008; 26(2):185-90. PubMed ID: 18301976
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
